SAN FP

Sanofi SA

Healthcare


Presented:07/25/2017
Price:€82.33
Cap:$118.92B
Current Price:€100.66
Cap:$140.54B

Presented

Date07/25/2017
Price€82.33
Market Cap$118.92B
Ent Value$120.36B
P/E Ratio11.8x
Book Value€45.91
Div Yield3.6%
Shares O/S1,296.84M
Ave Daily Vol2,451,004
Short IntN/A

Current

Price€100.66
Market Cap$140.54B
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Human Vaccines, and Animal Health. The Pharmaceuticals segment includes research, development, production and sales activities relating to pharmaceutical products, including prescription, consumer health care, and generic products. This segment also includes equity affiliates and joint ventures with pharmaceutical business activities. The Human Vaccines segment includes research, development, production and marketing of vaccines. The Animal Health segment comprises the research, development, production and marketing activities for Merial, which offers a range of medicines and vaccines for animal species. The company was founded on April 28, 1994 and is headquartered in Paris, France.

Publicly traded companies mentioned herein: Sanofi (SAN FP; SNY), Pfizer Inc (PFE), Regeneron (REGN)

Highlights

The presenter is long shares of Sanofi (SAN FP; SNY) at €83 and sees the risk/ reward as favorable given his long-term expectations for Dupixent (dupilumab), which was approved by the FDA on March 28, 2017 for the treatment of adults with moderate-to-severe atopic dermatitis (AD) - aka eczema. In his opinion, the Street is underestimating Dupixent’s potential market penetration and sales, as well as the potential for other new therapies to come to market as a result of the long-term Sanofi/ Regeneron collaboration. Thus, he views the stock as meaningfully undervalued at just 11x fully-taxed 2020 Street estimates, which appear to be too low. If his assessment of the situation and market opportunity for Dupixent are accurate, owning Sanofi is a low-risk way to a) own some of the best pieces of Regeneron’s portfolio/ pipeline; and b) realize upside to €120-135 over the next 12-24 months as its multiple expands (i.e., to 15x €8-9 of EPS in 2020).

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.